Accelerate Diagnostics Receives CARB-X Award to Develop Rapid Optical Imaging Technology for Sepsis and Antibiotic-Resistant Infections - News

Accelerate Diagnostics Receives CARB-X Award to Develop Rapid Optical Imaging Technology for Sepsis and Antibiotic-Resistant Infections

Jun 08, 2021

CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to accelerating research and development to address the rising global threat of drug-resistant bacteria, has awarded Accelerate Diagnostics up to $578,000 to develop new fiber optic technology to diagnose sepsis or the risk of sepsis. Accelerate would be eligible for up to $2.1 million in additional funds from CARB-X if the project meets certain milestones.

Accelerate Diagnostics Chief Executive Officer Jack Phillips said, “We are excited to receive this CARB-X award in support of this project as we continue to innovate in the fight against sepsis and antimicrobial resistance. This award will support our continuing efforts to develop better methods for delivering fast answers and improving clinical outcomes for patients with serious infections.”

Read the full CARB-X press release here.